CN105461715B - 一种利奥西呱中间体的合成方法 - Google Patents
一种利奥西呱中间体的合成方法 Download PDFInfo
- Publication number
- CN105461715B CN105461715B CN201510927765.4A CN201510927765A CN105461715B CN 105461715 B CN105461715 B CN 105461715B CN 201510927765 A CN201510927765 A CN 201510927765A CN 105461715 B CN105461715 B CN 105461715B
- Authority
- CN
- China
- Prior art keywords
- leo
- synthetic method
- compounds
- pyrazolos
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010189 synthetic method Methods 0.000 title claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 27
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 22
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960002587 amitraz Drugs 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000007787 solid Substances 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 14
- 229960004756 ethanol Drugs 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
- 235000019270 ammonium chloride Nutrition 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000005292 vacuum distillation Methods 0.000 claims description 5
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 238000012805 post-processing Methods 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 3
- 238000010009 beating Methods 0.000 claims description 2
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 2
- 239000012065 filter cake Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003785 thonzylamine Drugs 0.000 claims description 2
- 238000010792 warming Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 239000003054 catalyst Substances 0.000 abstract description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000977 initiatory effect Effects 0.000 abstract description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- QXAITBQSYVNQDR-ZIOPAAQOSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1/N=C/N(C)\C=N\C1=CC=C(C)C=C1C QXAITBQSYVNQDR-ZIOPAAQOSA-N 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 6
- 239000012535 impurity Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- RDRCCJPEJDWSRJ-UHFFFAOYSA-N pyridine;1h-pyrrole Chemical compound C=1C=CNC=1.C1=CC=NC=C1 RDRCCJPEJDWSRJ-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000020193 Pulmonary artery hypoplasia Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- -1 phenylazo Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 description 1
- 229960000529 riociguat Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510927765.4A CN105461715B (zh) | 2015-12-15 | 2015-12-15 | 一种利奥西呱中间体的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510927765.4A CN105461715B (zh) | 2015-12-15 | 2015-12-15 | 一种利奥西呱中间体的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105461715A CN105461715A (zh) | 2016-04-06 |
CN105461715B true CN105461715B (zh) | 2017-03-29 |
Family
ID=55599929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510927765.4A Active CN105461715B (zh) | 2015-12-15 | 2015-12-15 | 一种利奥西呱中间体的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105461715B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003095451A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
CN104530044A (zh) * | 2014-12-31 | 2015-04-22 | 安徽联创生物医药股份有限公司 | 一种利奥西呱的合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010021637A1 (de) * | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
-
2015
- 2015-12-15 CN CN201510927765.4A patent/CN105461715B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003095451A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
CN104530044A (zh) * | 2014-12-31 | 2015-04-22 | 安徽联创生物医药股份有限公司 | 一种利奥西呱的合成方法 |
Non-Patent Citations (1)
Title |
---|
"Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension";Joachim Mittendorf et al.;《ChemMedChem》;20090304;第4卷;第853-865页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105461715A (zh) | 2016-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102174020B (zh) | 合成有机化合物的方法 | |
CN104447445B (zh) | 一种合成阿普斯特中间体的制备方法 | |
CN105367557A (zh) | 一种环氧啉的制备方法 | |
CN105294534B (zh) | 制备阿普司特及其中间体的产业化方法 | |
CN104530044A (zh) | 一种利奥西呱的合成方法 | |
CN104926798B (zh) | 阿法替尼中间体的高纯度制备方法 | |
CN102617542B (zh) | 一种奥美沙坦中间体的制备方法及纯化方法 | |
CN107200705B (zh) | 一种3-硝基-2-吲哚酮衍生物的制备方法 | |
CN106187786B (zh) | 一种对氨基苯甲醚的清洁生产方法 | |
CN103483324A (zh) | 拉帕替尼的新制备方法 | |
CN101486687B (zh) | 一种盐酸司他斯汀的制备工艺 | |
CN105461715B (zh) | 一种利奥西呱中间体的合成方法 | |
CN104151251A (zh) | 一种一锅合成5-乙酰乙酰氨基苯并咪唑酮的方法 | |
CN103086959A (zh) | 一种生产3,5,6-三氯吡啶醇钠的新工艺 | |
CN105536873B (zh) | 一种复合催化剂及其应用 | |
CN101519407B (zh) | 一种可具有取代基的环酸酐的合成方法 | |
CN106188117A (zh) | 一种烷氧羰基苯硼酸的合成方法 | |
CN104130181B (zh) | 一种2,2,6,6-四甲基-4-哌啶酮的连续合成方法 | |
CN101638406A (zh) | 邻-羟甲基苯甲酸内酯的制备方法 | |
CN103709039A (zh) | Cu-丝光沸石催化合成没食子酸甲(乙)酯的方法 | |
CN111574384B (zh) | 一种手性1-氨基-2-丙醇的制备方法 | |
CN108147946A (zh) | 一种制备4-苯基苯酚的方法 | |
CN104276979B (zh) | 阿戈美拉汀中间体的制备方法 | |
CN105461656A (zh) | 一种制备沃替西汀的新工艺 | |
CN114835637B (zh) | 一种马来酸氯苯那敏的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240131 Address after: 730000, Zone C, Specialized and Special New Chemical Industry Incubation Base, Lanzhou New Area, Lanzhou City, Gansu Province Patentee after: Lanzhou Bosheng Kangyuan Pharmaceutical Co.,Ltd. Country or region after: China Address before: 22nd Floor, Alliance International, 125 Huanghe East Road, Jinshui District, Zhengzhou City, Henan Province, 450000 Patentee before: ZHENGZHOU DAMING DRUG SCIENCE & TECHNOLOGY CO.,LTD. Country or region before: China |